Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,954 shares of the biopharmaceutical company’s stock after purchasing an additional 1,561 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Regeneron Pharmaceuticals were worth $6,139,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. WPG Advisers LLC grew its position in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the period. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $31,000. Entrust Financial LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $32,000. Caitlin John LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $34,000. Finally, FNY Investment Advisers LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $38,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of Regeneron Pharmaceuticals stock opened at $628.73 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average price is $709.21 and its 200 day moving average price is $742.91. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The firm has a market capitalization of $66.47 billion, a PE ratio of 15.32, a P/E/G ratio of 1.37 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the company posted $8.22 EPS. The business’s revenue was up 19.0% on a year-over-year basis. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its strategic cancer partnership with CytomX to develop conditionally activated bispecific therapeutics, adding two new programs and optionality for more targets, which strengthens the company’s oncology pipeline and long-term growth prospects. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: Regeneron also said it will highlight new clinical data and research from its metabolic disease, ophthalmology, and rare disease pipelines at upcoming ADA and ENDO meetings, reinforcing investor focus on multiple potential catalysts beyond oncology. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Analyst and market commentary pointed to the expanded oncology collaboration and positive clinical trial updates as the reasons REGN shares moved higher, suggesting sentiment is being driven by pipeline optionality and business-development momentum. Why Regeneron (REGN) Stock Is Trading Up Today
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Regeneron investors, which could create headline risk, though the notice did not include any findings or financial impact. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Royal Bank Of Canada cut their price target on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research report on Monday, May 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Canaccord Genuity Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.